Compare ADMA Biologics Inc (ADMA) vs Global Payments Inc (GPN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Global Payments Inc — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Global Payments Inc trades at $74.53 (market cap $21.22B). The key difference: Global Payments Inc is far larger — about 10× ADMA Biologics Inc's market cap, and Global Payments Inc pays a 1.29% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | GPN | |
|---|---|---|
Market Cap | $2.13B | $21.22B |
Sector | Health | Industrials |
52-Week High | $20.38 | $90.01 |
52-Week Low | $7.60 | $62.47 |
Enterprise Value | $2.20B | $38.94B |
Dividend Yield | — | 1.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
GPN trades at $77.59, down 1.32% on the day, with a bullish technical outlook from moving averages but overbought RSI signals. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.96 exceeding expectations. Revenue for 2025 was $7.71 billion, though net income margin turned negative at -7.97% for 2026 projections. Analysts maintain a buy consensus with a $80 price target, citing growth from the Worldpay integration and new AI-powered POS launches.
The stock presents a mixed outlook: positive analyst sentiment and strategic expansions support upside, but margin pressures and rising debt pose risks. Investors should weigh the company's innovation against competitive fintech threats and macroeconomic headwinds affecting transaction volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →
